Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation

Annals of the American Thoracic Society

Volumn 12, Issue 5, 2015, Pages 708-717

  Sagel, Scott D ^a   Thompson, Valeria ^b   Chmiel, James F ^c   Montgomery, Gregory S ^d   Nasr, Samya Z ^e   Perkett, Elizabeth ^f   Saavedra, Milene T ^g   Slovis, Bonnie ^f   Anthony, Margaret M ^a   Emmett, Peggy ^h   Heltshe, Sonya L ⁱ  

^a Children's Hospital Colorado   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g DEPARTMENT OF MEDICINE   (United States)

^h CHILDREN S HOSPITAL COLORADO   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Cystic fibrosis; Inflammation; Plasma; Pulmonary exacerbation

Indexed keywords

ALPHA 1 ANTITRYPSIN; ARGINASE 1; CEFTAZIDIME; CERULOPLASMIN; GRANULOCYTE COLONY STIMULATING FACTOR; HAPTOGLOBIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE INHIBITOR; MEROPENEM; SERUM AMYLOID A; TOBRAMYCIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CELL COUNT; BODY MASS; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LEUKOCYTE COUNT; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; OXYGEN SATURATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY EXACERBATION; SYSTEMIC DISEASE; YOUNG ADULT; ADOLESCENT; CHILD; CLINICAL TRIAL; DISEASE COURSE; INFLAMMATION; LUNG; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; CHILD; CYSTIC FIBROSIS; CYTOKINES; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; LUNG; MALE; PROGNOSIS;

EID: 84929611597     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201410-493OC     Document Type: Article

References (36)

1. Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax 2012;67:882-890.
2. Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning of a new era. Am J Respir Crit Care Med 2012;186:593-597.
3. Mayer-Hamblett N, Ramsey BW, Kronmal RA. Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc 2007;4:370-377.
4. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2011;17:442-447.
5. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-808.
6. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007;4:406-417.
7. Shoki AH, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon BS. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013;144:1659-1670.
8. Sagel SD, Heltshe SL, Mayer-Hamblett N, Emmett P, Chmiel JF, Goss CH, Montgomery GL, Nasr SZ, Perkett E, Saavedra MT, et al. Changes in plasma biomarkers in CF pulmonary exacerbations [abstract]. Pediatr Pulmonol Suppl 2010;33:360.
9. Cystic Fibrosis Foundation. Clinical practice guidelines for cystic fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
10. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
11. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163.
12. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88.
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
14. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-632.
15. Dovey M, Aitken ML, Emerson J, McNamara S, Waltz DA, Gibson RL. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007;132:1212-1218.
16. Azar RR, Rinfret S, Théroux P, Stone PH, Dakshinamurthy R, Feng YJ, Wu AH, Rangé G, Waters DD. A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). Eur Heart J 2000;21:2026-2032.
17. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, Ghini AS, Ferrero V, Chiariello L, Gioffrè PA, et al.; Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation Study. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS study). J Am Coll Cardiol 2002;40:1935-1942.
18. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-765.
19. Gray RD, Imrie M, Boyd AC, Porteous D, Innes JA, Greening AP. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 2010;9:193-198.
20. Horsley AR, Davies JC, Gray RD, Macleod KA, Donovan J, Aziz ZA, Bell NJ, Rainer M, Mt-Isa S, Voase N, et al. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. Thorax 2013;68:532-539.
21. Moser C, Jensen PO, Pressler T, Frederiksen B, Lanng S, Kharazmi A, Koch C, Høiby N. Serum concentrations of GM-CSF and G-CSF correlate with the Th1/Th2 cytokine response in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. APMIS 2005;113:400-409.
22. Hartl D, Griese M, Kappler M, Zissel G, Reinhardt D, Rebhan C, Schendel DJ, Krauss-Etschmann S, Pulmonary T. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006;117:204-211.
23. Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, Dehlink E, Nachbaur E, Horak F, Jaksch P, et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013;187:621-629.
24. Pollard HB, Ji XD, Jozwik C, Jacobowitz DM. High abundance protein profiling of cystic fibrosis lung epithelial cells. Proteomics 2005;5:2210-2226.
25. Srivastava M, Eidelman O, Jozwik C, Paweletz C, Huang W, Zeitlin PL, Pollard HB. Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol Genet Metab 2006;87:303-310.
26. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med 2008;178:444-452.
27. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V, Emmett P, Marshall B, Accurso F, Sagel S, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012;142:1259-1266.
28. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001;31:436-442.
29. Kraynack NC, Gothard MD, Falletta LM, McBride JT. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011;46:870-881.
30. Brumback LC, Baines A, Ratjen F, Davis SD, Daniel SL, Quittner AL, Rosenfeld M; for the ISIS Study Group. Pulmonary exacerbations and parent-reported outcomes in children <6 years with cystic fibrosis. Pediatr Pulmonol [online ahead of print] 29 Apr 2014; DOI: 10.1002/ppul.23056.
31. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998;157:1764-1769.
32. Colombo C, Costantini D, Rocchi A, Cariani L, Garlaschi ML, Tirelli S, Calori G, Copreni E, Conese M. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. Pediatr Pulmonol 2005;40:15-21.
33. 1 in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy. Pediatr Pulmonol 2011;46:688-695.
34. Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168:1471-1475.
35. Downey DG, Brockbank S, Martin SL, Ennis M, Elborn JS. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007;42:729-735.
36. Reid PA, McAllister DA, Boyd AC, Innes JA, Porteous D, Greening AP, Gray RD. Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis. Am J Respir Crit Care Med 2015;191:233-236.